Moody's is concerned about Teva's debt and refinancing needs, Copaxone sales erosion, weak uptake of new drugs, and litigation risks.
Teva plunges again as Moody's revises outlook to negative - Globes
Read More
Moody's is concerned about Teva's debt and refinancing needs, Copaxone sales erosion, weak uptake of new drugs, and litigation risks.
No comments:
Post a Comment